Asco 2020 meeting
Harpoon Therapeutics | Harpoon Therapeutics, Inc.
At ASCO 2020, the Company also reported a 100% progression-free survival rate, 88% ORR and 3% CR rate, with a median follow-up of 12.8 months, for patients with chronic lymphocytic leukemia (“CLL”) treated with cirmtuzumab in combination with ibrutinib in the CIRLL study.
HER2-Directed Antibody-Drug Conjugates May Carve Out a Place i…
On June 1, 2020, Erytech Pharma S.A. (the “Company”) issued a press release announcing the presentation of two posters at the American Society of Clinical Oncology (ASCO) 2020 Virtual Meeting. A copy of the press release is attached to this Report on Form 6-K as Exhibit 99.1.
[DOCX File]Present Position
https://info.5y1.org/asco-2020-meeting_1_01332e.html
A copy of the poster will be available at the ASCO virtual meeting beginning today, May 29, 2020, at 8:00 AM ET. The poster and accompanying oral presentation by Sumanta (Monty) Pal, MD, Associate Clinical Professor, Department of Medical Oncology and Therapeutics Research, and Co-director, Kidney Cancer Program, at City of Hope Comprehensive ...
investors.erytech.com
ASCO is collaborating with the COVID-19 and cancer consortium and the American Society of Hematology (ASH) by sharing data collection tools with them and enabling joint analyses. ASCO can complement the work of other consortia and registries in part by better supporting community cancer practices.
[DOCX File]Stichting DUOS
https://info.5y1.org/asco-2020-meeting_1_0aaba2.html
Being held on Friday, June 12, and Saturday, June 13, 2020. Venue: Moffitt Cancer Center, Vincent A. Stabile Research Building, 12902 Magnolia Drive, Tampa, FL 33612. EXHIBIT INFO: FLASCO is inviting you to exhibit. We are expecting 100-125 attendees at Great Strides Together and 50-75 attendees during Rapid Integration.
Surface Oncology
Harpoon plans to present interim HPN424 data at the ASCO 2020 Virtual Meeting (Abstract 5552). The Company will host a virtual event to provide a clinical trial and pipeline update in parallel with the ASCO meeting. Anticipated 2020 Milestones. HPN424
Investor Relations | AVEO Oncology
Exhibit 99.1. Surface Oncology to Present at the American Society of Clinical Oncology Annual Meeting. CAMBRIDGE, Mass., May 14, 2020 -- Surface Oncology . (Nasdaq: SURF), a clinical-stage immuno-oncology company. developing next-generation immunotherapies that target the tumor microenvironment, today announced that data from the Phase 1 study of SRF231, a fully …
[DOCX File]Thanh Tung Uong
https://info.5y1.org/asco-2020-meeting_1_fb3e4b.html
Key findings of the study were presented at ASCO 2020 Virtual Meeting; Avelumab plus BSC significantly prolonged OS vs BSC alone (hazard ratio [HR] 0.69; [CI] 0.56, 0.86; 1-sided p = 0.0005). Median OS with avelumab plus BSC vs BSC alone was 21.4 vs 14.3
Investors | Oncternal Therapeutics, Inc.
June Draisey, Carly Rhodes, Terry Bourke, Vera Kind, Gilly Burns, Tiree Campbell (ASCO), Kamila Klidzia (ASCO), Foday Kamara (WBC) Minutes of Meeting: Minutes from 11.12.20149 unavailable at meeting – to be read at next meeting.
Health Level Seven International
May 29-June 2, 2020; ASCO Annual Meeting 2020 Presented Virtually; Abstract 538. Hertz DL , Larson N, Pierpont TM, Bartlett N, Zelenetz AD, Wilson W, Leonard J, Jung SH, Riska S, Richards KL Association of CEP72 rs924607 with vincristine-induced peripheral neuropathy (PN) in patients with diffuse large B-cell lymphoma on CALGB 50303 (Alliance).
Nearby & related entries:
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.